secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001437749-25-030719
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed new Phase 2b data: neflamapimod improves CDR-SB in DLB subgroup, reduces GFAP biomarker
--------------------------------------------------------------------------------

- In DLB patients with low AD co-pathology (ptau181<21 pg/mL), neflamapimod showed significant improvement on CDR-SB (p=0.005) in within-subject comparison to placebo.
- Neflamapimod reduced the risk of clinically meaningful progression by 75% vs placebo over 16 weeks (p<0.001).
- Plasma GFAP levels decreased by median -23.1 pg/mL on neflamapimod vs +5.8 on placebo (p=0.016); GFAP change correlated with CDR-SB.
- FDA feedback on Phase 3 trial design expected in Q4 2025.
- Two drug capsule batches were used; only the newer batch (NFMD/B) achieved target plasma concentrations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925030719/0001437749-25-030719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925030719/crvo20251008_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-030719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer